These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1627379)

  • 1. Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma.
    Alama A; Merlo F; Chiara S; Muttini MP; Guido T; Nicolò G; Conte PF; Ragni N
    Eur J Cancer; 1992; 28A(6-7):1079-80. PubMed ID: 1627379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour kinetics, response to chemotherapy and survival in primary ovarian cancer.
    Alama A; Chiara S; Merlo F; Ragni N; Conte PF; Meazza R; Reggiardo G; Ferrari I; Rosso R
    Eur J Cancer; 1994; 30A(4):449-52. PubMed ID: 8018401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine labeling index in epithelial ovarian cancer.
    Salihoglu Y; Bilir A; Aydiner A; Erkan M; Tuzlali S; Eralp Y
    Int J Gynaecol Obstet; 2001 Nov; 75(2):171-6. PubMed ID: 11684112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro thymidine labelling index in primary operable breast cancer.
    Holt S; Croton R; Leinster SJ; McDicken I; Nicholson RI; Cooke TG; George WD
    Eur J Surg Oncol; 1986 Mar; 12(1):53-7. PubMed ID: 3956755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of PCNA proliferating fraction for prognosis of ovarian carcinoma].
    Schönborn I; Minguillon C; Reles A; Bartel U; Lichtenegger W
    Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):357-64. PubMed ID: 8964450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival.
    Conte PF; Alama A; Rubagotti A; Chiara S; Nicolin A; Nicolò ; Rosso R; Gaddi M; Ghiringhello B; Tomao S
    Cancer; 1989 Sep; 64(6):1188-91. PubMed ID: 2766216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer.
    Barbieri F; Lorenzi P; Ragni N; Schettini G; Bruzzo C; Pedullà F; Alama A
    Oncology; 2004; 66(4):310-5. PubMed ID: 15218299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of ovarian carcinomas: prediction by histoquantitative methods.
    Haapasalo H; Collan Y; Atkin NB; Pesonen E; Seppä A
    Histopathology; 1989 Aug; 15(2):167-78. PubMed ID: 2777218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
    Raspollini MR; Amunni G; Villanucci A; Baroni G; Boddi V; Taddei GL
    J Chemother; 2003 Aug; 15(4):380-6. PubMed ID: 12962367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine labeling index: prognostic role in breast cancer.
    Bilir A; Ozmen V; Kecer M; Eralp Y; Cabioglu N; Ahishali B; Camlica H; Aydiner A
    Am J Clin Oncol; 2004 Aug; 27(4):400-6. PubMed ID: 15289735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.
    Massi D; Susini T; Savino L; Boddi V; Amunni G; Colafranceschi M
    Cancer; 1996 Mar; 77(6):1131-6. PubMed ID: 8635134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index.
    Silvestrini R; Daidone MG; Luisi A; Mastore M; Leutner M; Salvadori B
    Int J Cancer; 1997 Feb; 74(1):122-7. PubMed ID: 9036880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine labelling index as prognostic factor in resected non-small cell lung cancer.
    Alama A; Costantini M; Repetto L; Conte PF; Serrano J; Nicolin A; Barbieri F; Ardizzoni A; Bruzzi P
    Eur J Cancer; 1990; 26(5):622-5. PubMed ID: 2169278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell kinetics: a prognostic marker in epithelial ovarian cancer.
    Silvestrini R; Daidone MG; Bolis G; Fontanelli R; Landoni F; Andreola S; Colombi R
    Gynecol Oncol; 1989 Oct; 35(1):15-9. PubMed ID: 2676750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognostic significance of thymidine labelling index in primary breast cancer.
    Cooke TG; Stanton PD; Winstanley J; Murray GD; Croton R; Holt S; George WD
    Eur J Cancer; 1992; 28(2-3):424-6. PubMed ID: 1591056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced ovarian cancer. Neural network analysis to predict treatment outcome.
    Kappen HJ; Neijt JP
    Ann Oncol; 1993; 4 Suppl 4():31-4. PubMed ID: 8312198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of thymidine labelling index in breast cancer.
    Amadori D; Silvestrini R
    Breast Cancer Res Treat; 1998; 51(3):267-81. PubMed ID: 10068084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
    van Dalen A; Favier J; Baumgartner L; Hasholzner U; de Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Einarsson R
    Anticancer Res; 1999; 19(4A):2523-6. PubMed ID: 10470187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell kinetics in breast cancer.
    Becciolini A; Balzi M; Boanini P; Maugeri A; Pacini P; Bianchi S; Cardona G; Messeri G; Cataliotti L
    In Vivo; 1993; 7(6B):627-9. PubMed ID: 8193284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.